コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 with underlying chronic lymphocytic leukemia/small lymphocytic lymphoma.
2 refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.
3 reatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma.
4 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
5 with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.
6 sly treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
7 eatment-naive and relapsed/refractory CLL or small lymphocytic lymphoma.
8 lymphocytic leukaemia and two patients with small lymphocytic lymphoma.
9 patients with relapsed or refractory CLL or small lymphocytic lymphoma.
10 le exception of chronic lymphocytic leukemia/small lymphocytic lymphoma.
11 (P = 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma.
12 oma, and B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
13 first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma.
14 0.4, 0.4, 0.3; p trend = 0.03) with risk of small lymphocytic lymphoma.
15 arge B-cell and chronic lymphocytic leukemia/small lymphocytic lymphomas.
16 sed B-cell lymphomas, such as follicular and small lymphocytic lymphomas.
17 h high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with
18 non-Hodgkin's lymphomas, including cases of small lymphocytic lymphoma (18 cases), marginal zone lym
19 included follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma
20 refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma and at least two previous lin
21 ne and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leuke
23 ciation between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.
24 lymphoma (137 diffuse, 58 follicular, and 32 small lymphocytic lymphomas) and 63 cases of B-CLL were
25 ), and group C (chronic lymphocytic leukemia/small lymphocytic lymphoma, and other indolent lymphomas
27 lent lymphomas (6 marginal zone lymphomas, 7 small lymphocytic lymphomas, and 13 follicular lymphomas
29 iagnosis of chronic lymphocytic leukaemia or small lymphocytic lymphoma as per the International Work
30 s transplantation was found to have stage IV small lymphocytic lymphoma at the time of transplantatio
31 inal zone lymphoma (MZL), MALT lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient
32 r lymphoma (Case 1), follicular lymphoma and small lymphocytic lymphoma (Case 2), and mantle cell lym
36 luding 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other
38 mphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) but not for other N
39 hereas rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per y
40 analysis, RR of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was 1.66 (95% CI, 1
41 dicated that chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) was the principal N
42 Lymphoma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymp
46 5.41), but not chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; HR, 0.84; 95% CI, 0
48 kemias, such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 15), mantle cel
49 tic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade
50 an Alzheimer's disease dataset and a diffuse small lymphocytic lymphoma dataset reveals its ability t
51 y high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicula
52 y high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicula
53 of 39 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (diffusely positive in 33 cas
55 y untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or olde
56 brutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and dif
57 omas, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and man
58 refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed
59 d in 8 patients with relapsed/refractory CLL/small lymphocytic lymphoma harboring ATM deletions/mutat
60 /refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from t
61 in contrast to follicle center lymphoma and small lymphocytic lymphoma; however, pRB expression does
63 -2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specific
64 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3-4 anaem
65 refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma, including patients who had e
66 patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high
67 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk feat
68 ymptomatic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is encouraging, and merits fu
69 malignancies (chronic lymphocytic leukaemia, small lymphocytic lymphoma, mantle cell lymphoma, Walden
70 center B cells (chronic lymphocytic leukemia/small lymphocytic lymphomas, mantle cell lymphomas, and
72 in 41% (mainly chronic lymphocytic leukemia/small lymphocytic lymphoma), monoclonal gammopathy in 20
73 ients with R/R marginal zone, follicular, or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsiv
74 phoma (n = 3), mantle cell lymphoma (n = 2), small lymphocytic lymphoma (n = 2), and myeloid leukemia
75 zone (n = 4), lymphoplasmacytic (n = 1), or small lymphocytic lymphoma (n = 3); and CLL (n = 11), we
76 a (n=50), marginal zone lymphoma (n=30), and small lymphocytic lymphoma (n=30) were enrolled from Jun
77 ohort (n=14 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=10 B-cell non-Hodgkin lymp
78 cohort (n=9 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=13 B-cell non-Hodgkin lymp
81 nib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for
82 y activation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle
83 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma reaching undetectable MRD in
84 ated del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma received oral ibrutinib 420 m
85 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy
86 1.16, 1.96) and chronic lymphocytic leukemia/small lymphocytic lymphoma (relative risk = 1.93, 95% co
87 tment-naive chronic lymphocytic leukaemia or small lymphocytic lymphoma, required therapy, and were a
90 0.17-0.78) and chronic lymphocytic leukemia/small lymphocytic lymphoma (RR, 0.46; 95% CI, 0.21-1.01)
91 d or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of
92 leukocyte CITE-seq data and matched diffuse small lymphocytic lymphoma scRNA-seq and scATAC-seq data
95 included eight chronic lymphocytic leukemia/small lymphocytic lymphomas, six mantle cell lymphomas,
96 ractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymph
98 s with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-pha
99 s with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes afte
100 d follicular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic
101 n well characterized and its relationship to small lymphocytic lymphoma (SLL) or chronic lymphocytic
102 The effect was most pronounced for the CLL/small lymphocytic lymphoma (SLL) subtype (OR: 1.0; 3.2 [
103 ents with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at
104 patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharm
105 with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) treated with a previous
106 d BNT162b2 mRNA vaccine in patients with CLL/small lymphocytic lymphoma (SLL) who failed to achieve a
107 ents with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The Un
108 ents with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of re
109 sed in non-Hodgkin's lymphoma (NHL), such as small lymphocytic lymphoma (SLL), and many other cancers
110 ax in treatment-naive (TN) patients with CLL/small lymphocytic lymphoma (SLL), in a large population
116 come was compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocy
117 has been reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leu
118 lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's mac
119 f 237 tumors (10.5%), which included 1 of 45 small lymphocytic lymphomas (SLLs), 2 of 38 follicular s
120 the risk of the chronic lymphocytic leukemia/small lymphocytic lymphoma subtype among women only (253
122 iagnosis of chronic lymphocytic leukaemia or small lymphocytic lymphoma to Richter transformation was
123 pposite associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance
124 International Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase
125 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma were recruited from two acade
126 ed were CPP32 immunopositive, whereas 3 of 3 small lymphocytic lymphomas were CPP32 negative, suggest
127 with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma who received at least one dos
128 had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node di
129 regimen in chronic lymphocytic leukaemia and small lymphocytic lymphoma with treatment duration guide
130 herapy for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of u